Celyad Starts a Third CAR-T Trial, in Metastatic Colorectal Cancer

Celyad has started the SHRINK trial, which will evaluate the synergistic effects of the company’s CAR-T technology in combination with chemotherapy. 

After recently reporting impressive 3-month results in colorectal cancer, Celyad has decided to start a third Phase I trial with its CAR-T therapy, which is based on the NKR-2 receptor of natural killer cells and has the potential to target 80% of tumors. This new trial will test whether the immunotherapy can improve efficacy in combination with chemotherapy in patients with metastatic colorectal cancer.

Celyad has already successfully completed a Phase I trial, CM-CS1, in acute myeloid leukemia and multiple myeloma. It is now testing CAR-T NKR2 in another trial (THINK) focusing on five solid tumor types: ovarian, colorectal, pancreas, bladder and triple-negative breast. Confident on the potential of its therapy to treat multiple tumor types, the company plans to start a fourth CAR-T trial, called LINK, in which the engineered cells will be infused via catheter near metastases to increase their concentration in the tumor site.


Image via Juan Gartner / Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.